



Malta, 27 March 2006

PLU 01/2006

Report on the European Commission Assessment of the Community System of Pharmacovigilance.

The objective of this assessment is to analyse how the European central agency (EMA) and the EU Member States' national competent agencies collaborate with each other, the marketing authorisation holders (MAHs) and other stakeholders, in the surveillance of adverse effects of medicinal products, and to put forward recommendations to make the system more robust. The final report has been issued by the European Commission for public consultation and can be accessed on:

http://pharmacos.eudra.org/F2/pharmacovigilance_acs/index.htm